Compared with last year, what changes have been made to new drugs in the world? August 09, 2016 Source: Minenet Although anticancer drugs have dominated the development of new drugs for many years, the rapid growth of new drug research and development in this field in the past year is attributed to the rapid development of tumor immunology and will have a profound impact on the future. This article analyzes the drug status of the 16 major therapeutic areas and biotechnology categories in the Pharmaprojects/Pipeline database, and further analyzes the breakdown of treatment categories and indications to find new features in the development of new drugs. Analysis of 16 major therapeutic areas Cancer therapeutic drugs dominate According to the classification of new drug projects in 16 major therapeutic areas, it was found that the number of new drugs under development in each therapeutic field basically showed a growth trend in 2016. Through the Pharmaprojects/Pipeline database data, the status of the drug under investigation in 16 major therapeutic areas and biotechnology categories can be analyzed. On the whole, anticancer drugs, biotechnology drugs, nervous system drugs, anti-infective drugs and compound drugs rank among the top 5 therapeutic areas. Among them, cancer is still the core area of ​​drug research and development, and the number of anti-cancer/anti-tumor drugs has increased significantly. The number has increased from 3602 in 2015 to 4176, an increase of 15.9%, far exceeding the average growth rate of 11.5% in the pharmaceutical R&D industry. . This also means that almost one-third (32.8%) of the drugs under development are aimed at cancer diseases. In addition, treatment areas with growth rates exceeding the industry's average growth rate include biotech medications (up 14.6%), sensory medications (up 13.5%), and immunological drugs (up 11.8%). Among the several drug fields in which the number of drugs in the research ranks relatively high, the increase in cardiovascular system drugs (4.6% increase), anti-infective drugs (6.2% increase), and nervous system drugs (7.7% increase) is relatively high. low. From the available statistics, cancer treatment drugs are occupying a dominant position in the development of new drugs. According to the specific analysis, the rapid growth of anti-cancer/anti-tumor drugs is largely due to the development of tumor immunology. I believe that the future of cancer immunology will gain more opportunities for development. 228 segmentation category analysis Two types of anticancer drugs top the list The 16 therapeutic areas of the drug were subdivided into 228 treatment categories for further analysis, compared with the 2015 data, reflecting changes in the number of drugs being studied in different treatment categories. From the TOP 25 ranking of treatment categories, general anticancer drugs (2071 in research drugs), immune anticancer drugs (1597), preventive vaccines (729), diabetes treatment drugs (592), and other ophthalmic drugs (546) are the top five treatment categories, which are in the same order as in 2015. Overall, compared with 2015, most of the major treatment categories showed a trend of product line expansion, and two major types of anti-cancer/anti-tumor drugs ranked first. Compared with the growth rate of general anticancer drugs, immune anticancer drugs have grown more rapidly, and the number of drugs under research has increased by 25.6%, indicating that these drugs have received more attention in the past year, and the product line has developed more rapidly. Most notably, the number of drugs in the field of gene therapy has increased from 294 in 2015 to 417, an increase of 41.8%, the most obvious growth rate. This class of drugs returned to the top 25 in 2015, and In 2012 and 2014, they both fell out of the TOP 25 ranks. Among these treatment categories, cell therapy is the first treatment category to enter the TOP25 ranks in recent years. Analysis of 1450 indications Anti-cancer heavy drug "extrusion effect" Further statistics according to the indications of the drug under study can be classified into 1,450 diseases or indications, of which more than 470 diseases are rare diseases recognized by official or authoritative organizations. Compared with the ranking in 2015, there was no significant change in the ranking order of each indication. Currently, the global TOP 5 indications for research include breast cancer (614 in the study), non-small cell lung cancer (452), colorectal cancer (431), pancreatic cancer (390) and type 2 diabetes ( 386). Among them, breast cancer continued to rank first, with the number of drugs under research increasing by 11.2% year-on-year; non-small cell lung cancer ranked second with an increase of 14.1%; colorectal cancer was only 4.4%, ranking from The second place in 2015 slipped to the third place; the growth rate of pancreatic cancer was the most obvious. In 2016, 51 drugs were added to the drug, and the growth rate of 15.0% jumped from the ninth place in 2015 to Fourth place. Among the top 15 disease categories, the indications for growth are mainly cancer. In addition to the top five cancer categories, there are ovarian cancer (374), brain cancer (287) and liver cancer (241). ), the increase was 9.4%, 11.7% and 9.5% respectively. The cancer categories included in TOP 25 include acute myeloid leukemia (232), head and neck cancer (221), myeloma (218), non-Hodgkin's lymphoma (216), and gastrointestinal cancer (196). And kidney cancer (186). Systemic neuropathic pain (167) is the new TOP25 cancer category this year. Compared with other types of drugs, anti-tumor drugs are often used in the treatment of a variety of diseases, so from the statistical data, anti-cancer / anti-tumor drugs will rank higher. Of course, this also means that the blockbuster drugs for treating cancer have a certain crowding effect on the indications or the application of relatively narrow drugs. In addition to breast cancer (11.2% increase), non-small cell lung cancer (14.1% increase), pancreatic cancer (15.0% increase), and brain cancer (11.7% increase), Acute myeloid leukemia (18.4% increase), head and neck cancer (up 15.7%), myeloma (19.1% increase), and gastrointestinal cancer (16.0% increase) were the categories of indications with faster growth. Kn95 5 Layers Mask,Kn95 Filters Face Mask,Kn95 5 Layers Cup Facemask,Kn95 5 Layers Fold Flat Facemask Jiangmen anjian biotechnology co. LTD , https://www.jmanjianmask.com
Compared with last year, what changes have been made to new drugs in the world?
Next Article
Dangui green seedlings autumn maintenance
Prev Article
Winter dry skin itching how to make up the skin